The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.
The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.
复制标题
DOI：
10.1177/2042018818766816
复制
发表时间：
2018-07
影响因子：
3.8
通讯作者：
Parekh W
中科院分区：
文献类型：
--
作者：
Leelarathna L;Ashley D;Fidler C;Parekh W
速效门冬胰岛素是速效胰岛素类似物门冬胰岛素的一种新制剂，在起效和餐后血糖控制方面代表了优于当前速效胰岛素类似物的进步。当前分析的目的是证明处方速效门冬胰岛素而非门冬胰岛素的成本影响，以强调速效门冬胰岛素在治疗需要餐时胰岛素的糖尿病患者中的价值。从英国国民保健服务（NHS）的角度进行了成本影响分析。该分析排除了患者的自付费用，护理人员的费用和生产力损失。分析的时间范围为1年，因此未应用贴现。对于英国NHS而言，用速效门冬胰岛素替代门冬胰岛素的成本是中性的。速效门冬胰岛素在药瓶和笔芯方面与门冬胰岛素价格相同，FlexTouch®注射笔的价格与门冬胰岛素FlexPen®相同（因此比门冬胰岛素FlexTouch®注射笔便宜）。使用门冬胰岛素FlexPen®的患者在转换为速效门冬胰岛素后，将升级为患者和医疗保健专业人员首选的FlexTouch®笔装置，无需额外费用。与门冬胰岛素相比，速效门冬胰岛素提供了额外的临床获益，但没有额外的成本，因此为英国NHS提供了价值。
Fast-acting insulin aspart is a new formulation of the rapid-acting insulin analogue insulin aspart and represents an advancement over current rapid-acting insulin analogues in terms of onset of action and postprandial glucose control. The objective of the current analysis was to demonstrate the cost impact of prescribing fast-acting insulin aspart instead of insulin aspart, to highlight the value of fast-acting insulin aspart for the treatment of people with diabetes requiring mealtime insulin. A cost-impact analysis was conducted from the perspective of the UK National Health Service (NHS). The analysis excluded patients’ out-of-pocket expenses, carers’ costs and lost productivity. The time horizon of the analysis was 1 year, and no discounting was therefore applied. The displacement of insulin aspart with fast-acting insulin aspart is cost neutral for the UK NHS. Fast-acting insulin aspart is at price parity to insulin aspart in terms of the vial and Penfill® cartridge and is available in the FlexTouch® pen at the same price as the insulin aspart FlexPen® (and thus cheaper than the insulin aspart FlexTouch® pen). Patients using the insulin aspart FlexPen® will be upgraded to the FlexTouch® pen device, which is preferred by patients and healthcare professionals, on switching to fast-acting insulin aspart, at no additional cost. Fast-acting insulin aspart offers additional clinical benefit but at no additional cost when compared with insulin aspart, and thus provides value to the UK NHS.
登录
查看更多内容
影响因子：
2.3
作者：
Bailey, T.;Thurman, J.;Schmeisl, G.
通讯作者：
Schmeisl, G.
影响因子：
16.2
作者：
Bowering, Keith;Case, Christopher;Bode, Bruce W.
通讯作者：
Bode, Bruce W.
影响因子：
3.1
作者：
Bailey, Timothy;Campos, Carlos
通讯作者：
Campos, Carlos
影响因子：
5.8
作者：
Cavalot, F;Petrelli, A;Trovati, M
通讯作者：
Trovati, M
影响因子：
--
作者：
Borch-Johnsen, K;Neil, A;Qiao, Q
通讯作者：
Qiao, Q